The aim of this study was to identify an eff ective fl avonoid that could improve the intracellular accumulation of ritonavir in human brain-microvascular endothelial cells (HBMECs). An in vivo experiment on Sprague-Dawley rats was then designed to further determine the fl avonoid's impact on the pharmacokinetics and tissue distribution of ritonavir. In the accumulation assay, the intracellular leve l of ritonavir was increased in the presence of 25 mmol L -1 of fl avonoids in HBMECs. Quercetin showed the strongest eff ect by improving the intracellular accumulation of ritonavir by 76.9 %. In the pharmacokinetic study, the presence of quercetin in the co-administration group and in the pretreatment group signifi cantly decreased the area under the plasma concentration-time curve (AUC 0-t ) of ritonavir by 42.2 % (p < 0.05) and 53.5 % (p < 0.01), and decreased the peak plasma concentration (c max ) of ritonavir by 23.1 % (p < 0.05) and 45.8 % (p < 0.01), respectively, compared to the control group (ritonavir alone). In the tissue distribution study, the ritonavir concentration in the brain was signifi cantly increased 2-fold (p < 0.01), during the absorption phase (1 h) and was still signifi cantly higher (p < 0.05) during the distribution phase (6 h) in the presence of quercetin.
effl ux transporters in the blood-brain barrier (BBB), which include members of the ATP--binding cassett e superfamily of proteins, such as P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP), and breast cancer resistance protein (BCRP) (6) . The HIV-1 pro tease inhibitors (HPIs) are key components of the HAART currently used to treat HIV-1 infection. A strong body of evidence suggests that HPIs are substrates of P-gp and, as a result, the limited ability of these drugs to transverse the BBB is att ributed to the activity of this effl ux transporter (7) (8) (9) (10) (11) . A recent study showed that MDR1 specifi c drug-effl ux function increases in BBB following co-exposure to HIV-1 and HPIs, which can reduce the penetration of HPIs into the infected brain reservoirs of HIV-1 (12) .
To overcome tumor cell resistence caused by the over-expression of P-gp, a chemosensitizer is used to inhibit the effl ux pump activity (13, 14) . In principle, a similar strategy could be employed for HPIs therapy in order to enhance their distribution into sites such as the brain. Compounds such as verapamil, quinidine, and cyclosporin A have shown inhibitory eff ects on P-gp function. However, these compounds have an intrinsic toxicity due to their pharmacological activity and cannot be used safely at dosages required for the inhibition of drug effl ux in vivo. Although some competitive inhi bit or s of P-gp are being tested as an approach to increase HPIs levels within the brain, their g eneralized inhibition has not been a safe or feasible approach since other organs also suff er from toxic xenobiotics (15) . The search for chemosensitizers, which have the advantage of being eff ective inhibitors without side-eff ects, has focused on plant-derived fl av onoids (16) . Flavonoids are constituents of fruits, vegetables, herbal dietary supplements, as well as components of traditional Chinese m edicines, and several fl avonoids have been proven to modulate the function and expression of P-gp (17) (18) (19) .
This study was designed to seek a safe and eff ective fl avonoid to be used as an agent to increase HPIs levels within the brain, and to determine whether the result of fl avonoids in vitro screening can be translated to in vivo eff ects on the distribution of HPIs into the brain.
EXPERIMENTAL

Chemicals
Ritonavir was purchased from Xiamen Henry Biochem Co., Ltd. (China). Saquinavir (an internal standard for high performance liquid chromato graphy-tandem mass chromatogra phy, HPLC-MS/MS, analysis of ritonavir) with a purity > 99% was from United States Pharmacopoeia USA). Epicatechin gallate (ECG), hesperetin, kaempferol, quercetin, isoq uercetrin, morinhydrate, chrysin and epicatechin (EC) (purity ≥ 99 %) were purchased from Nantong Feiyu Biological Technology Co., Ltd. (China). Verapamil was obtained from the China National Institute for Food and Drug Control (China). HPLC-grade methanol, acetonitrile, methyl tert-butyl ether, sodium tetraborate, ammonium formate and formic acid were purchased from Fisher Scientifi c Co. (USA). Bicinchoninic acid (BCA) protein assay kit and bov ine serum albumin (BSA) were purchased from Tiangen Biotech (China). Distilled water was purifi ed by a Derect-Q ® Ultrapure Water System (Millipore, USA). The mobile phase used in HPLC-MS/MS was fi ltered using a 0.45-μm membrane fi lter, and was supplied by Ameritech Co. (USA).
Animals
Sprague-Dawley rats (6-10 weeks old, half male and half f emale, 250-300 g) were purchased from the Academy of Military Medical Sciences (Beĳ ing, China) and raised in the animal room of the Peking University People's Hospital (Beĳ ing, China), under a 12-h light-dark cycle. The animals were housed with free access to laboratory food and water ad libitum. Exp erimental procedures were reviewed and approved by the Ethics Committ ee of the Peking University People's Hospital, and were designed in accordance with the "Guide for the Care and Use of Laboratory Animals".
Cell culturing
Hum an brain-microvascular endothelial cells (HBMECs) were obtained from the Cell Bank of Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). HBMECs were incubated at 37 °C and in the presence of 5 % CO 2 in Roswell Park Memorial Institute (RPMI) 1640 medium supplemented by 10 % heat-inactivated fetal bovine serum, antibiotics (penicillin 100 U mL -1 , streptomycin 100 μg mL -1 ), and 2 mmol L -1 L-glutamine (all from Gibco/BRL, Germany). HBMECs whose monlayers reached confl uence were selected and the old media were discarded. The cells were washed twice with phosphate-buff ered saline (PBS) at 37 °C. A 0.25 % trypsin-EDTA solution was then added to the cells at about 0.12 mL cm -2 . Aft er incubation at 37 °C for 15 min, the solution was discarded and new culture medium was added. The cells att ached to the wall were gently fl uctuated with the medium using a transfer pipett e until the cells were detached and suspended. The cell density was adjusted to approximately 5 × 10 4 mL -1 , and the cells were inoculated in a new culture fl ask. The medium was replaced every other day for regular cellular metabolism and the cells were subcultured approximately every three days in order to maintain proper cell density.
Intracellular accumulation of riton avir
Accumulation of ritonavir in HBMECs was examined in confl uent cell cultures as previously described (20, 21) . HBMECs were seeded into a 6-well plate, at 2 × 10 4 cells per well. When cells were 70-80 % confl uent, aft er the addition of 50 μmol L -1 of ritonavir, either 25 μmol L -1 of various fl avonoids or 100 μmol L -1 verapamil (the drugs were dissolved in solvent with less than 1 % of the RPMI 1640 by volume was added, except for the blank control. Cells were then incubated for another 4 hours in a CO 2 incubator to reach a steady-state level. The cells were then rinsed ten times with the ice-cold PBS in a culture dish to remove the drugs on the cell surface. Aft er the addition of 500 μL of de-ionized water, the cells were transferred into a micro centrifuge tube with a cell scraper. The culture dish and cell scraper were rinsed with 500 μL of de-ionized water and the suspension was then transferred into micro centrifuge tube. The cell suspension was processed with an ultrasonic cell disruption system 40 times (working frequency 10, disruption 3 s, interval 3 s). The lysate solution was centrifuged for 5 min at 13400 rpm, and the supernatant was kept at -20 °C until HPLC-MS/MS analysis.
Pharmacokinetic study
For the phar maco kinetic study, eighteen Sprague-Dawley rats were randomly divided into three groups (n = 6, half male and half female). The rats in the control group were orally administered ritonavir at a dose of 20 mg kg -1 bm aft er being orally administered a blank solvent for 7 consecutive days. The rats of co-administration group were orally coadmini stered ritonavir at a dose of 20 mg kg -1 and quercetin at a dose of 100 mg kg -1 bm, aft er being orally administered a blank solvent for 7 consecutive days. The rats of pretreatment group were orally administered ritonavir at a dose of 20 mg kg -1 with quercetin at a dose of 100 mg kg -1 , aft er being orally pretreated with 100 mg kg -1 quercetin for 7 consecutive days. The rats were fasted for 12 hours prior to the beginning of experiments (on the eighth day) and had free access to sterilized water.
Aft er oral admin istration blood samples (200 μL) were collected into heparinized centrifuge tubes a t predetermined time intervals of 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 and 48 hours from the retro orbital vein using heparinized capillary tubes. Control blood samples were obtained before dosing. Blood samples were immediately centrifuged for 5 min at 12,000 rpm, and a 100-μL aliquot of plasma was stored in a freezer at -20 °C until HPLC-MS/MS analysis.
Tissue distribution study
For the tissue distribution study, 36 Sprague-Dawley rats were randomly divided into 2 groups (n = 18, half male and half female). The rats were fasted for 12 h prior to the beginning of experiments and had free access to sterilized water. The rats were orally given a dose of 20 mg kg -1 of ritonavir with or without quercetin (100 mg kg -1 ). For the control, a blank solvent was given in comparable amounts (5 mL kg -1 ). At each of the time points (1, 6 and 12 h) following dosing, six rats were sacrifi ced and brain, liver and kidney tissues were collected. Tissue samples were rinsed with physiological saline to remove blood or content, weighed, blott ed on filter paper, and then stored in a freezer at -20 °C until HPLC-MS/MS analysis.
HPLC-MS/MS quantitative analysis of ritonavir
Conditions. -High performance liquid chr omatography was performed using an Agilent 1200 HPLC system consisting of a G1312A binary pump, a G1379B degasser, a G1329A autosampler and a G1316A column oven (Agilent, USA). Ritonavir was separated on a Resteck Ultra C18 column (150 × 2.1 mm i.d., 5.0 μm, USA) maintained at 20 ± 0.5 °C (amb ient temperature of the la boratory). The mixed mobile phase delivered at 300 μL min Optimized MS parameters were: curtain gas, gas 1 (nitrogen), and gas 2 (nitrogen) 206.85, 275.8 and 275.8 kPa, respectively, dwell time 200 ms, ionspray voltage +4500 V, ion source temperature 500 °C, declustering potential (DP) 0 V for ritonavir, and 0 V for the internal standard; collision energy (CE) -26 V for ritonavir and -46 V for the internal standard (volt is a standard unit of parameters in the instrument). Data acquisition and analysis were performed using the analyst soft ware version 1.5.1 (Applied Biosystems, Foster City, CA, USA).
Ritonavir in HBMECs.
-The intracellular concentration of ritonavir in HBMECs was determined by HPLC-MS/MS. No eff ect on cell viability was observed at these concentrations during the incubation period (data not shown). Results were normalized to the protein content of cells in each well (22, 23) . The protein content in the lysate solution of cells was determined using the commercially available BCA protein assay. The acc umulation of ritonavir was expressed as uptake per mg protein of the cells relative to the drug concentration (ng kg -1 protein).
Ritonavir in blood plasma. 
Pharmacokinetics
The pharmacokinetic parameters of ritonavir wer e analyzed by non-compartmental analysis using the PK-Solver Program (version 2.0, China Medicinal University, Nanjing, China). The elimination rate constant (K el ) was calculated by log-linear regression of ritonavir concentration data during the elimination phase, and the terminal half-life (t 1/2 ) was calculated as 0.693/K el . The peak concentration (c max ) of ritonavir in plasma as well as the time to reach c max (t max ), were obtained by visual inspection of the data from the concentration-time curve. The area under the plasma concentration-time curve (AUC) from time zero to the time of the last measured concentration (c last ) was calculated by means of the linear trapezoidal rule. AUC 0-∞ was determined by adding AUC 0-t , and the extrapolated area was determined by calculating c last /K el . Mean residence time (MRT) was the estimated time for 63.2 % of the administered dose to be eliminated. The total body clearance of oral (Cl/F, here F represents the bioavailability of ritonavir) ritonavir was calculated from the quotient of the dose and the AUC 0-∞ .
Data analysis
All analyses were performed using SPSS (SPSS 11.0, SPSS, Inc., Chicago, USA). For comparisons of the mean values between two experimental groups, Student's unpaired t-test was used. Comparisons between three or more experimental groups were performed using a one-way analysis of variance, followed by Dunnett 's test. Diff erences were considered statistically signifi cant when p < 0.05.
RESULTS AND DISCUSSION
HPLC-MS/MS validation
The method was checked according to the guidelines for bioanalytical method validation. The calibration curve for ritonavir was linear over the concentration range 0.1-100 ng mL -1 , which were found to be adequate for the analysis of the lysate solution of cells, plasma and tissues. The quantitation limit, with a coeffi cient of variation of less than 20 %, was 0.1 ng mL -1 . Inter-and intra-day coeffi cients of variation for the low, middle, and high quality control samples were less than 15 %. Ritonavir was found stable when kept at 25 °C for 24 h, at -20 °C for 30 days, and aft er 3 freeze-thaw cycles.
Eff ect of fl avonoids on intracellular accumulatio n of ritonavir in HBMECs
In the accumulation assay, the intracellular level of ritonavir in HBMECs was measured aft er 4 h of incubation with various fl avonoids (Fig. 1) . The positive control verapamil at 100 μmol L -1 signifi cantly increased (p < 0.01) the intracellular accumulation of ritonavir by 133.2 % compared to the control (ritonavir alone). Among the eight fl avonoids, hesperetin, quercetin, isoquercetin and EC demonstrated signifi cant eff ects on the accumulation of ritonavir in HBMECs, with quercetin showing the strongest eff ect, with an increase of 76.9 %. In other words, the results indicated that quercetin had the highest potential for inhibiting P-gp, the important effl ux transporter in the cell membrane. 
Eff ect of quercetin on pharmacokinetics of orally administered ritonavir
The mean arterial plasma concentration-time profi les of ritonavir following oral administration in the presence or absence of quercetin are illustrated in Fig. 2 and the pharmacokinetic parameters of ritonavir are summarized in Table I . Compared to the control group (ritonavir alone), the presence of quercetin in the co-administration group and the pretreatment gro up signifi cantly decreased AUC 0-t of ritonavir by 42.2 % (p < 0.05) and 53.5 % (p < 0.01), and markedly decreased the peak plasma concentration (c max ) of ritonavir by 23.1 % (p < 0.05) and 45.8 % (p < 0.01), respectively. The time to reach maximum plasma concentration (t max ) was postponed and the Cl/F of ritonavir was increased in the presence of quercetin. In addition, no signifi cant changes in t 1/2 and MRT of ritonavir were found aft er quercetin co-administration either the co-administration group or the pretreatment group.
Eff ect of quercetin on tissue distribution of orally administered ritonavir
The tissue distribution results of orally administered ritonavir in the absence or presence of quercetin are shown in Table II . The ritonavir concentration in the brain was markedly increased (p < 0.01), by 205.3 %, during the absorption phase (1 h), and was still signifi cantly higher (p < 0.05) than the contro l during the distribution phase (6 h) when Fig. 2 . Mean plasma concentration-time profi les of ritonavir in rats. (•) Mean plasma concentration-time profi les of ritonavir in the control group rats, which were orally administered ritonavir (20 mg kg -1 bm) aft er being administered orally blank solvent for 7 consecutive days; () mean plasma concentrationtime profi les of ritonavir in the co-administration group, which were orally co-administered ritonavir (20 mg kg -1 bm) with quercetin (100 mg kg -1 bm), aft er being orally administered blank solvent for 7 consecutive days; () mean plasma concentration-time profi les of ritonavir in the pretreatment group rats which were orally co-administered ritonavir (20 mg kg -1 bm) with quercetin (100 mg kg -1 bm) aft er being orally pretreated with quercetin (100 mg kg -1 bm) for 7 consecutive days. Data are represented as mean ± SD (n = 6). Insert: enlarged portion of up to 6 hours. AUC 0-t -area under the plasma concentration-time curve from time zero to the time of last measured concentration, c max -peak concentration; t max -time to reach peak concentration, t 1/2 -terminal half-life, MRT, mean residence time, Cl/F -total body clearance, F -bioavailability. co-administrated with quercetin. There were no signifi cant changes for ritonavir concentration in the brain in the elimination phase (12 h), with or without quercetin. Ritonavir concentration in the liver was signifi cantly increased (p < 0.01), by 72.3 %, during the distribution phase (6 h), and showed no signifi cant change in the absorption phase (1 h) or elimination phase either (12 h). However, the ritonavir concentration in the kidney tissue decreased markedly (p < 0.01), by 42.4 %, during the elimination phase (12 h) but had no signifi cant changes either during the absorption (1 h) or distribution phase (6 h).
It can be seen that there was a wide changing range of SD within the parameters in Table II . One reason is that all the analyses were based on the data of 6 experimental animals in each group, which could be considered as a small sample size. Other reasons are still to be explored. K. Berginc et al. (24) investigated the impact of garlic fl avonoids on the hepatic pharmacokinetics of saquinavir and darunavir. It was very confusing that aged garlic extract signifi cantly inhibited saquinavir effl ux from rat hepatocytes, while the effl ux of darunavir signifi cantly increased. The authors inferred that the competition between saquinavir and garlic constituent(s) for the same binding site on the effl ux transporter and the positive cooperative eff ect between darunavir and garlic phytochemical(s), which bind to separate binding places on the transporter, are the most probable mechanisms. In our study, ritonavir was used as the test drug, whose chemical structure is different from saquinavir and darunavir, so the exact mechanism is still unclear. We must admit that the current manuscript is just a primary exploratory study and our group will consistently investigate the detailed mechanism in the future.
Summary of the study
In this study, we assessed the eff ects of eight fl avonoids on the accumulation of ritonavir in HBMECs and found that quercetin was the most eff ective in improving the intracellular concentration of ritonavir. Further, the in vivo experiment sought to determine if quercetin could serve as an agent to improve the brain concentration of ritonavir in rats. Based on the results of animal experiments, we found that quercetin had a signifi cant eff ect on the pharmacokinetics of ritonavir in rats. Aft er co-administration with quercetin, the postponed t max in rats demonstrated tha t the absorption of ritonavir was slowed down. The AUC 0-t and c max were decreased, which indicated that the amount of ritonavir exposed in plasma was reduced. However, the concentration of ritonavir in the brain increased signifi cantly when orally co-administrated with quercetin. The results of tissue studies were consistent with the results of the intracellular accumulation assay of ritonavir in HBMECs. Many reports indicate that fl avonoids modulate the cell multi-drug resistance mediated by P-gp (25) (26) (27) , which plays a role in the barrier function of BBB. As ritonavir is a substrate of P-gp, modulating P-gp might be a mechanism that could improve the concentration of ritonavir in the brain. Quercetin, which has a consistent eff ect on the modulation of ritonavir in vitro and in vivo, might become a safe and eff ective agent for increasing HP Is levels within the brain.
CONCLUSIONS
This study found that quercetin screened from the in vitro experiment had a significant eff ect on the pharmacokinetics of ritonavir in rat s and could markedly enhance the distribution of ritonavir into the brain in vivo. These fi ndings suggest a new strategy that might result in higher brain distributions reduced toxicity, and improved effi cacy of HPIs by using a plant-derived fl avonoid as a chemosensitizer.
